Evidence map›Paper›PMID 27449292›Full record

ArticleOncotarget2016

Beta protein 1 homeoprotein induces cell growth and estrogen-independent tumorigenesis by binding to the estrogen receptor in breast cancer.

Sidney W Fu, Saurabh P Kirolikar, Erika Ginsburg, Xiaohui Tan, Arnold Schwartz, Samuel J Simmens, Yan-Gao Man, Joseph J Pinzone, Christine Teal, Sanket Awate and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Sidney W FuDepartment of Medicine, Division of Genomic Medicine, George Washington University, Washington, DC 20037, USA.
Saurabh P KirolikarDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Erika GinsburgMammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Xiaohui TanDepartment of Medicine, Division of Genomic Medicine, George Washington University, Washington, DC 20037, USA.
Arnold SchwartzDepartment of Pathology, George Washington University Medical Center, Washington, DC 20037, USA.
Samuel J SimmensDepartment of Epidemiology and Biostatistics, School of Public Health and Health Services, George Washington University, Washington, DC 20037, USA.
Yan-Gao ManDepartment of Gynecologic and Breast Pathology, Armed Forces Institute of Pathology, Washington, DC 20306, USA.
Joseph J PinzoneDavid Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA.
Christine TealDepartment of Surgery, George Washington University, Washington, DC 20037, USA.
Sanket AwateDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
Barbara K VonderhaarMammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Patricia E BergDepartment of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA.
George Washington University · USArmed Forces Institute of Pathology · USNational Cancer Institute · USNational Institutes of Health · USUniversity of California, Los Angeles · USWashington University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expression of Beta Protein 1 (BP1), a homeotic transcription factor, increases during breast cancer progression and may be associated with tumor aggressiveness. In our present work, we investigate the influence of BP1 on breast tumor formation and size in vitro and in vivo. Cells overexpressing BP1 showed higher viability when grown in the absence of serum (p < 0.05), greater invasive potential (p < 0.05) and formed larger colonies (p < 0.004) compared with the controls. To determine the influence of BP1 overexpression on tumor characteristics, MCF-7 cells transfected with either empty vector (V1) or overexpressor plasmids (O2 and O4) were injected into the fat pads of athymic nude mice. Tumors grew larger in mice receiving O2 or O4 cells than in mice receiving V1 cells. Moreover, BP1 mRNA expression levels were positively correlated with tumor size in patients (p = 0.01). Interestingly, 20% of mice injected with O2 or O4 cells developed tumors in the absence of estrogen, while no mice receiving V1 cells developed tumors. Several mechanisms of estrogen independent tumor formation related to BP1 were established. These data are consistent with the fact that expression of breast cancer anti-estrogen resistance 1 (BCAR1) was increased in O2 compared to V1 cells (p < 0.01). Importantly, O2 cells exhibited increased proliferation when treated with tamoxifen, while V1 cells showed growth inhibition. Overall, BP1 overexpresssion in MCF-7 breast cancer cells leads to increased cell growth, estrogen-independent tumor formation, and increased proliferation. These findings suggest that BP1 may be an important biomarker and therapeutic target in ER positive breast cancer.

Indexed as

Cell ProliferationAnimalsBreast NeoplasmsCarcinogenesisEstrogensFemaleGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMCF-7 CellsMice, NudeProtein BindingReceptors, EstrogenTranscription FactorsTransplantation, HeterologousTumor BurdenDLX4 protein, humanEstrogensHomeodomain ProteinsReceptors, EstrogenTranscription FactorsBP1estrogen receptorhomeobox genetamoxifen resistancetumorigenesis

Identifiers

PMID27449292
PMCPMC5288179
OpenAlexW2464592516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.